Fracture prevention in postmenopausal women.
Mosekilde
Leif
L
Faculty of Health sciences, University of Aarhus and Dept of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus C, Denmark.
Vestergaard
Peter
P
Langdahl
Bente
B
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D004002:Clodronic Acid / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D020249:Hormone Replacement Therapy; D006801:Humans; D000077557:Ibandronic Acid; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D000077268:Pamidronate; D010281:Parathyroid Hormone / Q000627:therapeutic use; D000068296:Risedronic Acid; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D010281:Parathyroid Hormone; D020845:Selective Estrogen Receptor Modulators; D004002:Clodronic Acid; D014807:Vitamin D; D002116:Calcitonin; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077268:Pamidronate; D002118:Calcium; D000077557:Ibandronic Acid; D019386:Alendronate